Advertisement

Drug Safety

, Volume 38, Issue 2, pp 117–128 | Cite as

Safety Surveillance of Traditional Chinese Medicine: Current and Future

  • Shwu-Huey Liu
  • Wu-Chang Chuang
  • Wing Lam
  • Zaoli Jiang
  • Yung-Chi Cheng
Leading Article

Abstract

Herbal medicine, including traditional Chinese medicine, has been used for the prevention, treatment, and cure of disorders or diseases for centuries. In addition to being used directly as therapeutic agents, medicinal plants are also important sources for pharmacological drug research and development. With the increasing consumption of herbal products intended to promote better health, it is extremely important to assure the safety and quality of herbal preparations. However, under current regulation surveillance, herbal preparations may not meet expectations in safety, quality, and efficacy. The challenge is how to assure the safety and quality of herbal products for consumers. It is the responsibility of producers to minimize hazardous contamination and additives during cultivation, harvesting, handling, processing, storage, and distribution. This article reviews the current safety obstacles that have been involved in traditional Chinese herbal medicine preparations with examples of popular herbs. Approaches to improve the safety of traditional Chinese medicine are proposed.

Keywords

Traditional Chinese Medicine Herbal Product Aristolochic Acid Botanical Drug Traditional Chinese Medicine Formula 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

The authors thank Christopher C. Chen for scientific editorial assistance with this article. This work was supported by the National Cancer Institute (Grant No. 1PO1CA154295-01A1). Yung-Chi Cheng is a fellow of the National Foundation for Cancer Research, USA.

Disclaimer

The views expressed in this article are personal and do not reflect the official position or policies of the authors’ respective organizations.

Conflict of interest

Yung-Chi Cheng, Shwu-Huey Liu, and Zaoli Jiang are the co-inventors of PHY906 patents. Wu-Chang Chuang and Wing Lam have no conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Barnes PM, Bloom B, Nahin R. CDC National Health Statistics Report #12. Complementary and alternative medicine use among adults and children: United States, 2007. 10 Dec 2008.Google Scholar
  2. 2.
    Nahin R, Barnes PM, Stussman BJ, et al. CDC National Health Statistics Report #18. Costs of complementary and alternative medicine (CAM) and frequency of visits to CAM practitioners: United States, 2007. 30 July 2009.Google Scholar
  3. 3.
    Fouladbakhsh JM, Stommel M, Given BA, Given CW. Pedictors of use of complementary and alternative therapies among patients with cancer. Oncol Nurs Forum. 2005;32(6):1115–22.CrossRefPubMedGoogle Scholar
  4. 4.
    Friesen D. Traditional Chinese Medicine: Business blockbuster or false fad? CKGSB Knowledge. http://knowledge.ckgsb.edu.cn/2013/01/08/china/traditional-chinese-medicine-business-blockbuster-or-false-fad/. 8 Jan 2013.
  5. 5.
    Luo Xiwen tr. Bencao Gangmu: compendium of materia medica. vol 6. Foreign Languages Press; 2003.Google Scholar
  6. 6.
    Maoshiny N. The yellow Emperor’s Classic of Medicine: a new translation of the Neijing suwen with commentary. Shambhala Publications, Inc.; 1995.Google Scholar
  7. 7.
    Division of Health Statistics. Statistical Annual Report of Medical Care, National Health Insurance. Taipei: The ROC Department of Health; 2009.Google Scholar
  8. 8.
  9. 9.
    Borum ML. Fulminant exacerbation of autoimmune hepatitis after the use of ma huang. Am J Gastroenterol. 2001;96(5):1654–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Powell T, Hsu FF, Turk J, Hruska K. Ma-huang strikes again: ephedrine nephrolithiasis. Am J Kidney Dis. 1998;32(1):153–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Fan TP, Deal G, Koo HL, et al. Future development of global regulations of Chinese herbal products. J Ethnopharmacol. 2012;140(3):568–86.CrossRefPubMedGoogle Scholar
  12. 12.
    Hughes D. New EU regulations on herbal medicines come into force. BBC News. 2011.Google Scholar
  13. 13.
    Zhang L, Yan J, Liu X, et al. Pharmacovigilance practice and risk control of traditional Chinese medicine drugs in China: current status and future perspective. J Ethnopharmacol. 2012;10(140):519–25.CrossRefGoogle Scholar
  14. 14.
    Dietary supplements. U.S. Food and Drug Administration Web site. Accessed at www.fda.gov/Food/DietarySupplements.
  15. 15.
    Liu SH, Cheng YC. Old formula, new Rx: the journey of PHY906 as cancer adjuvant therapy. J Ethnopharmacol. 2012;140(3):614–23.CrossRefPubMedGoogle Scholar
  16. 16.
    FDA. Guidance for Industry. Botanical Drug Products (FDA, DC, June 2004). http://www.fda.gov/cder/guidance/4592fnl.pdf.
  17. 17.
    Wu KM, Farrelly J, Birnkrant D, et al. Regulatory toxicology perspectives on the development of botanical drug products in the United Sates. Am J Ther. 2004;11:213–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Veregen: a botanical for treatment of genital warts. Obstet Gynecol. 2008;112(3):691–2.Google Scholar
  19. 19.
    Tradtrantip L, Namkung W, Verkman AS. Crofelemer, an antisecretory antidiarrheal proanthocyanidin oligomer extracted from Croton lechleri, targets two distinct intestinal chloride channels. Mol Pharmacol. 2010;77(1):69–78.CrossRefPubMedCentralPubMedGoogle Scholar
  20. 20.
    Teschke R, Wolff A, Frenzel C, Schulze J. Review article: herbal hepatotoxicity—an update on traditional Chinese medicine preparations. Aliment Pharmacol Ther. 2014;40(1):32–50.CrossRefPubMedGoogle Scholar
  21. 21.
    Chen SP, Ng SW, Poon WT, Lai CK, et al. Aconite poisoning over 5 years: a case series in Hong Kong and lessons towards herbal safety. Drug Saf. 2012;35(7):575–87.CrossRefPubMedGoogle Scholar
  22. 22.
    Nyirimigabo E, Xu Y, Li Y, et al. A review on phytochemistry, pharmacology and toxicology studies of Aconitum. J Pharm Pharmacol. 2014 [Epub ahead of print].Google Scholar
  23. 23.
    Shaw D. Toxicological risks of Chinese herbs. Planta Med. 2010;76(17):2012–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Haller CA, Dyer JE, Ko R, Olson KR. Making a diagnosis of herbal-related toxic hepatitis. West J Med. 2002;176(1):39–44.CrossRefPubMedCentralPubMedGoogle Scholar
  25. 25.
    Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet. 1993;341:387–91.CrossRefPubMedGoogle Scholar
  26. 26.
    Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N Engl J Med. 2000;342(23):1686–92.CrossRefPubMedGoogle Scholar
  27. 27.
    Vanherweghem LJ. Misuse of herbal remedies: the case of an outbreak of terminal renal failure in Belgium (Chinese herbs nephropathy). J Altern Complement Med. 1998;4(1):9–13.CrossRefPubMedGoogle Scholar
  28. 28.
    Chen CH, Dickman KG, Huang CY, et al. Aristolochic acid-induced upper tract urothelial carcinoma in Taiwan: clinical characteristics and outcomes. Int J Cancer. 2013;133(1):14–20.CrossRefPubMedGoogle Scholar
  29. 29.
    Hoang ML, Chen CH, Sidorenko VS, et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome sequencing. Sci Transl Med. 2013;5:197ra102.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Drew AK, Whyte IM, Bensoussan A, et al. Chinese herbal medicine toxicology database: monograph on Herba Asari, “xi xin”. J Toxicol Clin Toxicol. 2002;40(2):169–72.CrossRefPubMedGoogle Scholar
  31. 31.
    Lee CH, Wang JD, Chen PC. Risk of liver injury associated with Chinese herbal products containing Radix bupleuri in 639,779 patients with Hepatitis B virus infection. PLoS One. 2011;6(1):e16064.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Xue X, Xiao Y, Gong L, et al. Comparative 28-day repeated oral toxicity of Longdan Xieganwan, Akebia trifoliate (Thunb.) koidz., Akebia quinata (Thunb.) Decne. and Caulis aristolochiae manshuriensis in mice. J Ethnopharmacol. 2008;119(1):87–93.CrossRefPubMedGoogle Scholar
  33. 33.
    Hsu HY, Hsu CS. Commonly used Chinese herb formulas with illustrations. Los Angeles: Oriental Healing Art Institute; 1980.Google Scholar
  34. 34.
    Pharmacopoeia of the People’s Republic of China. vol 1, 1997.Google Scholar
  35. 35.
    Fu PP, Yang YC, Xia Q, et al. Pyrrolizidine alkaloids-tumorigenic components in Chinese herbal medicines and dietary supplements. J Food Drug Anal. 2002;10(4):198–211.Google Scholar
  36. 36.
    Cohen PA, Maller G, DeSouza R, et al. Presence of banned drugs in dietary supplements following FDA recalls. JAMA. 2014;312(16):1691–3.CrossRefPubMedGoogle Scholar
  37. 37.
    Blum D. The trouble with rice. N Y Times. 2014. http://nyti.ms/1eIX0T4
  38. 38.
    Meharg AA. Arsenic in rice—understanding a new disaster for South-east Asia. Trends Plant Sci. 2004;9:415–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Moreno-Jiménez E, Meharg AA, Smolders E, et al. Sprinkler irrigation of rice fields reduces grain arsenic but enhances cadmium. Sci Total Environ. 2014;1(485–486):468–73.CrossRefGoogle Scholar
  40. 40.
    Harris ESJ, Cao S, Littlefield BA, et al. Heavy metal and pesticide content in commonly prescribed individual raw Chinese herbal medicines. Sci Total Environ. 2011;409(20):4297–305.CrossRefPubMedCentralPubMedGoogle Scholar
  41. 41.
    Genuis SJ, Schwalfenberg G, Siy A-KJ, Rodushkin I. Toxic element contamination of natural health products and pharmaceutical preparations. Sem DS, editor. PLoS One. 2012;7(11):e49676.Google Scholar
  42. 42.
    Lee KH, Morris-Natschke SL, Yang X, et al. Recent progress of research on medicinal mushrooms, foods, and other herbal products used in traditional Chinese medicine. J Tradit Complement Med. 2012;2(2):84–95.PubMedCentralPubMedGoogle Scholar
  43. 43.
    Zuo HL, Chen SJ, Zhang DL, et al. Quality evaluation of natural Cordyceps sinensis from different collecting places in China by the contents of nucleosides and heavy metals. Anal Methods. 2013;5:5450–6.CrossRefGoogle Scholar
  44. 44.
    Wu TN, Yang KC, Wang CM, et al. Lead poisoning caused by contaminated Cordyceps, a Chinese herbal medicine: two case reports. Sci Total Environ. 1996;182(1–3):193–5.CrossRefPubMedGoogle Scholar
  45. 45.
    Chen LL, Zhou X, Zhang YX, et al. Chemical composition and Heavy metal content of radix of Panax notoginseng from different sources. In: Proceedings of the 13th Meeting of Consortium for Globalization of Chinese Medicine. 2014.Google Scholar
  46. 46.
    Zhang MY, Xie J, Zhang TY, et al. Sinomonas notoginsengisoli sp. nov., isolated from the rhizosphere of Panax notoginseng. Antonie Van Leeuwenhoek. 2014;106(4):827–35.CrossRefPubMedGoogle Scholar
  47. 47.
    Bhattacharyya P, Jha DK. Plant growth-promoting rhizobacteria (PGPR): emergence in agriculture. World J Microbiol Biotechnol. 2012;28:1327–50.CrossRefPubMedGoogle Scholar
  48. 48.
    Greenpeace. Chinese Herbs: elixir of health or pesticide cocktail [report on the internet]. Available from: http://www.greenpeace.org/eastasia/campaigns/food-agriculture/Chinese-Herbs-Elixir-of-Health/.
  49. 49.
    Michael W. Mystery malady kills more bees, heightening worry on farms. N Y Times. 2013. http://www.nytimes.com/2013/03/29/science/earth/soaring-bee-deaths-in-2012-sound-alarm-on-malady.html
  50. 50.
    Simon RA. Adverse reactions to drug additives. J Allergy Clin Immunol. 1984;74:623.CrossRefPubMedGoogle Scholar
  51. 51.
    Kan WL, Ma B, Lin G. Sulfur fumigation processing of traditional Chinese medicinal herbs: beneficial or detrimental? Front Pharmacol. 2011;27(2):84.Google Scholar
  52. 52.
    Wu J, Shen H, Xu J, et al. Detection of Sulfur-fumigated Paeoniae Alba Radix in complex preparations by high performance liquid chromatography tandem mass spectrometry. Molecules. 2012;17:8938–54.CrossRefPubMedGoogle Scholar
  53. 53.
    Asgarpanah J, Kazemivash N. Phytochemistry, pharmacology and medicinal properties of Carthamus tinctorius L. Chin J Integr Med. 2013;19(2):153–9.CrossRefPubMedGoogle Scholar
  54. 54.
    Rao WW, Jiang L, Zhao CY, et al. Identification of chemical industry dyes in adulteration of Chinese medicinal materials. J Pharm Anal. 2007;27(11):1742–5.Google Scholar
  55. 55.
    Liu SH, Cheng YC, Saif MW. Controlling chemotherapy-related side effects with Chinese medicine. Chapter 7 of “Supportive Cancer Care with Chinese Medicine”. Springer Science; (2010).Google Scholar
  56. 56.
    White J. PC-SPES-A Lesson for future dietary supplement research. J Natl Cancer Inst. 2002;94(17):1261–2.CrossRefPubMedGoogle Scholar
  57. 57.
    Olaku O, White JD. Herbal therapy use by cancer patients: a literature review on case reports. Eur J Cancer. 2011;47(4):508–14.CrossRefPubMedCentralPubMedGoogle Scholar
  58. 58.
    Meyer JP, Gillatt DA. PC-SPES: a herbal therapy for the treatment of hormone refractory prostate cancer. Prostate Cancer Prostatic Dis. 2002;5(1):13–5.CrossRefPubMedGoogle Scholar
  59. 59.
    DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med. 1998;339(12):785–91.CrossRefPubMedGoogle Scholar
  60. 60.
    Small EJ, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol. 2000;18:3595–603.PubMedGoogle Scholar
  61. 61.
    De la Taille A, Hayek OR, Burchardt M, et al. Role of herbal compounds (PC-SPES) in hormone-refractory prostate cancer: two case reports. J Altern Complement Med. 2000;6:449–51.CrossRefPubMedGoogle Scholar
  62. 62.
    De la Taille A, et al. Effects of a phytherapeutic agent, PC-SPES, on prostate cancer: a preliminary investigation on human cell lines and patients. BJU Int. 1999;84:845–50.CrossRefPubMedGoogle Scholar
  63. 63.
    Sovak M, Seligson AL, Konas M, et al. Herbal composition PC-SPES for management of prostate cancer: identification of active principles. J Natl Cancer Inst. 2002;94(17):1275–81.CrossRefPubMedGoogle Scholar
  64. 64.
    Woolf GM, Petrovic LM, Rojter SE, Wainwright S, et al. Acute hepatitis associated with the Chinese herbal product jin bu huan. Ann Intern Med. 1994;121(10):729–35.CrossRefPubMedGoogle Scholar
  65. 65.
    Picciotto A, Campo N, Brizzolara R, et al. Chronic hepatitis induced by jin bu huan. J Hepatol. 1998;28:165–7.CrossRefPubMedGoogle Scholar
  66. 66.
    Horowitz RS, Feldhaus K, Dart RC. The clinical spectrum of Jin Bu Huan toxicity. Arch Intern Med. 1996;156(8):899–903.CrossRefPubMedGoogle Scholar
  67. 67.
    FAO (Food and Agriculture Organization of United Nations). Manual on the Application of the HACCP System in Mycotoxin Prevention and Control, 73, FAO Food and Nutrition Paper, Rome. 2001.Google Scholar
  68. 68.
    Zain ME. Impact of mycotoxins on humans and animals. J Saudi Chem Soc. 2011;15:129–44.CrossRefGoogle Scholar
  69. 69.
    Ashiq S, Hussain M, Ahmad B. Natural occurrence of mycotoxins in medicinal plants: a review. Fungal Genet Biol. 2014;66:1–10.CrossRefPubMedGoogle Scholar
  70. 70.
    Kneifel W, Czech E, Kopp B. Microbial contamination of medicinal plants—a review. Planta Med. 2002;68(1):5–15.CrossRefPubMedGoogle Scholar
  71. 71.
    Melchart D, Linde K, Weidenhammer W, Hager S, Shaw D, et al. Liver enzyme elevations in patients treated with traditional Chinese medicine. JAMA. 1999;282(1):28–9.CrossRefPubMedGoogle Scholar
  72. 72.
    Itoh S, Marutani K, Nishijima T, Matsuo S, Itabashi M. Liver injuries induced by herbal medicine, syo-saiko-to (xiao-chai-hu-tang). Dig Dis Sci. 1995;40(8):1845–8.CrossRefPubMedGoogle Scholar
  73. 73.
    Seeff L, Stickel F, Navarro VJ. Hepatotoxicity of herbals and dietary supplements. In: Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier; 2013. p. 631–58.CrossRefGoogle Scholar
  74. 74.
    Schieman C, Rudmik LR, Dixon E, et al. Complementary and alternative medicine use among general surgery, hepatobiliary surgery and surgical oncology patients. Can J Surg. 2009;52(5):422–6.PubMedCentralPubMedGoogle Scholar
  75. 75.
    Li X, Yang G, Li X, et al. Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in Chinese. PLoS One. 2013;8(4):e60338.CrossRefPubMedCentralPubMedGoogle Scholar
  76. 76.
    Gurley BJ, Swain A, Williams DK, et al. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: Comparative effects of St. John’s wort, echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res. 2008;52(7):772–9.CrossRefPubMedCentralPubMedGoogle Scholar
  77. 77.
    Lou SK, Wong KL, Li M, et al. An integrated web medicinal materials DNA database: MMDBD (Medicinal Materials DNA Barcode Database). BMC Genomics. 2010;24(11):402.CrossRefGoogle Scholar
  78. 78.
    Song J, Yao H, Li Y, Li X, Lin Y, Liu C, Han J, Xie C, Chen S. Authentication of the family Polygonaceae in Chinese pharmacopoeia by DNA barcoding technique. J Ethnopharmacol. 2009;124:434–9.CrossRefPubMedGoogle Scholar
  79. 79.
    Yan M, Chen JL, Xu LW, et al. Navigating traditional Chinese medicine network pharmacology and computational tools. Evid Based Complement Alternat Med. 2013;2013:731969.Google Scholar
  80. 80.
    Ye M, Liu SH, Jiang Z, et al. Liquid chromatography/mass spectrometry analysis of PHY906, a Chinese medicine formulation for cancer therapy. Rapid Commun Mass Spectrom. 2007;21(22):3593–607.CrossRefPubMedGoogle Scholar
  81. 81.
    Tilton R, Paiva AA, Guan JQ, et al. A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906. Chin Med. 2010;20(5):30.CrossRefGoogle Scholar
  82. 82.
    Zhang W, Saif MW, Dutschman GE, et al. Identification of chemicals and their metabolites from PHY906, a Chinese medicine formulation, in the plasma of a patient treated with irinotecan and PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). J Chromatogr A. 2010;1217(37):5785–93.CrossRefPubMedCentralPubMedGoogle Scholar
  83. 83.
    Dunnick JK, Nyska A. The toxicity and pathology of selected dietary herbal medicines. Toxicol Pathol. 2013;41(2):374–86.CrossRefPubMedGoogle Scholar
  84. 84.
    Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine: how to practice and teach EBM. Edinburgh: Churchill Livingstone; 2000.Google Scholar
  85. 85.
    Pelkonen O, Xu Q, Fan TP. Why is research on herbal medicinal products important and how can we improve its quality. J Tradit Complement Med. 2014;4(1):1–7.CrossRefPubMedCentralPubMedGoogle Scholar
  86. 86.
    O’Brien KA, Ling S, Abbas E, et al. A chinese herbal preparation containing radix salviae miltiorrhizae, radix notoginseng and borneolum syntheticum reduces circulating adhesion molecules. Evid Based Complement Alternat Med. 2011;2011:790784.PubMedCentralPubMedGoogle Scholar
  87. 87.
    Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina (CAESA) ClinicalTrials.gov Identifier: NCT01659580.Google Scholar
  88. 88.
    Lam W, Bussom S, Guan F, et al. PHY906, a four-herb Chinese medicine formula first described 1,800 years ago, reduces irinotecan-induced intestinal damage through anti-inflammatory effects and by promotion of the repopulation of intestinal progenitor cells. Sci Transl Med. 2010;2(45):45ra59.CrossRefPubMedGoogle Scholar
  89. 89.
    Wang E, Bussom S, Chen J, et al. Interaction of a traditional chinese medicine (PHY906) and CPT-11 on the inflammatory process in the tumor microenvironement. BMC Med Genomics. 2011;4:38.CrossRefPubMedCentralPubMedGoogle Scholar
  90. 90.
    Yen Y, So S, Rose M, et al. Phase I/II study of PHY906/capecitabine in advanced hepatocellular carcinoma. Anticancer Res. 2009;29(10):4083–92.PubMedGoogle Scholar
  91. 91.
    Saif MW, Lansigan F, Ruta S, et al. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and gastrointestinal malignancies. Phytomedicine. 2010;17(3–4):161–9.CrossRefPubMedGoogle Scholar
  92. 92.
    Kummar S, Copur MS, Rose M, et al. A phase I study of the Chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2011;10(2):85–96.CrossRefPubMedGoogle Scholar
  93. 93.
    Saif MW, Li J, Lamb L, et al. First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer. Cancer Chemother Pharmacol. 2014;73(2):373–80.CrossRefPubMedCentralPubMedGoogle Scholar
  94. 94.
    Villanueva T. Therapy: good old herbs. Nature Rev Cancer. 2010;10:664.CrossRefGoogle Scholar
  95. 95.
    Eng C. Are herbal medicines ripe for the cancer clinic? Sci Transl Med. 2010;2(45):45ps41.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  • Shwu-Huey Liu
    • 1
  • Wu-Chang Chuang
    • 2
  • Wing Lam
    • 1
  • Zaoli Jiang
    • 1
  • Yung-Chi Cheng
    • 1
  1. 1.Department of PharmacologyYale University School of MedicineNew HavenUSA
  2. 2.Brion Research Institute of TaiwanNew Taipei CityTaiwan, ROC

Personalised recommendations